These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18251347)

  • 1. How are drugs approved? Part 1: the evolution of the Food and Drug Administration.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Jan; 46(1):15-9. PubMed ID: 18251347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How are drugs approved? Part 3. The stages of drug development.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of drug development in the United States and current challenges.
    Moore SW
    South Med J; 2003 Dec; 96(12):1244-55; quiz 1256. PubMed ID: 14696877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Federal Drug Administration authority and the emergency nurse: implications for patient safety.
    Hackenschmidt A
    J Emerg Nurs; 2006 Oct; 32(5):449-50. PubMed ID: 16997042
    [No Abstract]   [Full Text] [Related]  

  • 5. How are drugs approved? Part 2: ethical foundations of clinical research.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Feb; 46(2):15-20. PubMed ID: 18293779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Warns Against Unregulated Products.
    Aschenbrenner DS
    Am J Nurs; 2018 Mar; 118(3):22-23. PubMed ID: 29470211
    [No Abstract]   [Full Text] [Related]  

  • 9. Managing oncology research protocols.
    Lunik MC
    Top Hosp Pharm Manage; 1994 Jul; 14(2):11-21. PubMed ID: 10136201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
    Tylenda CA; Weintraub M
    Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. It is time for food and drug administration reform.
    Guharoy R
    Arch Intern Med; 2010 Apr; 170(8):737. PubMed ID: 20421564
    [No Abstract]   [Full Text] [Related]  

  • 12. The FDA process for the evaluation and approval of orthopaedic devices.
    Kirkpatrick JS; Stevens T
    J Am Acad Orthop Surg; 2008 May; 16(5):260-7. PubMed ID: 18460686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategically aligned Food and Drug Administration: New ways to leverage research and deliver safe, effective, and secure devices for trauma care.
    Kumar A; Schwartz S
    J Trauma Acute Care Surg; 2015 Oct; 79(4 Suppl 2):S75-7. PubMed ID: 26406439
    [No Abstract]   [Full Text] [Related]  

  • 16. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE; Farrell AT; Pazdur R; Woodcock J
    Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.